Back to search results

AAC-BeT Study for Anxiety and Depression

This study, called AAC-BeT, is looking into better ways to treat anxiety and depression, which are common conditions. Current treatments don't always provide long-lasting relief for everyone. This study compares three different behavioral therapies: Behavioral Activation (which helps you engage in meaningful activities), Exposure-based therapy (which helps you face fears and reduce avoidance), and Supportive therapy (which encourages you to talk openly about your feelings). Researchers want to see which of these 10-week therapies works best, especially for people experiencing both anxiety and depression. Success will be measured by changes in your anxiety and depression symptoms over about 18 weeks. You might be able to join if you are 18 to 65 years old, have significant anxiety and depression symptoms, and can speak English well. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 220 participants. It compares three different behavioral therapies.
What's involved
You would participate in one of three 10-week behavioral interventions. Your anxiety and depression symptoms will be measured for up to 18 weeks after the start of the study.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 18 weeks after their initial assessments to measure changes in symptoms.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04426461

Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)

Completed
NAAges 18–65InterventionalBasic science
Laureate Institute for Brain Research, Inc.
~260 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Behavioral ActivationExposure-based therapySupportive therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite score from Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression (HAM-D)
Measured over Up to 18 weeks after the baseline assessments
+1 more outcome measured

Conditions

Anxiety
Depression

Explore related trials

AnxietyDepression

NCT04426461

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Laureate Institute for Brain Research

    Tulsa, Oklahomano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Robin L Aupperle, PhD · PRINCIPAL_INVESTIGATOR · Laureate Institute for Brain Research

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

score \>55 on both the PROMIS Anxiety and PROMIS Depression scales
score \>5 on any one item of the SDS
able to provide informed consent
report of anxiety and depressive symptoms as areas of clinical concern
sufficient English proficiency to complete procedures.

Exclusion

significant or unstable physical or mental health conditions (e.g., immediate suicidal intent) requiring medical attention
history of bipolar, psychotic, cognitive, obsessive compulsive disorder, posttraumatic stress disorder (PTSD)
history of moderate to severe substance use disorder over the past year
diagnosis of neurologic disorders
MRI contra-indications (e.g., metal in body)
uncorrected vision/hearing problems
current, regular benzodiazepine use

What this trial measures

  • Composite score from Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression (HAM-D)Up to 18 weeks after the baseline assessments

    Composite score (averaging of the standardized Z scores) from the Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression (HAM-D). These Z scores will range from -3.0 to +3.0, with greater scores indicating more severe anxiety and depression symptoms or worse outcome.

  • Quinolinic AcidUp to 18 weeks after the baseline assessments

    Peripheral serum concentration of Quinolinic Acid